About the Company
We do not have any company description for SOLENO THERAPEUTICS INC at the moment.
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic Apparatus
Employees
27
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on SOLENO THERAPEUTICS INC
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for ...
Soleno Therapeutics stock falls after Scorpion Capital short report
Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $108.70 Consensus ...
Soleno Therapeutics has a 12 month low of $41.50 and a 12 month high of $90.32. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -17.67 and a beta of -2.56.
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Soleno Therapeutics, Inc. to Participate in February Investor ...
Soleno Therapeutics, Inc. announced its participation in two upcoming investor conferences in February 2025. The company will host a fireside chat at the Guggenheim SMID Cap Biotech Conference on ...
Soleno Therapeutics, Inc. Announces $200 Million Public ... - Nasdaq
Soleno Therapeutics, Inc. announced its plan to conduct a public offering for $200 million in shares of its common stock, with an option for underwriters to purchase an additional $30 million in ...
Charles Schwab Investment Management Inc. Buys 24,953 Shares of Soleno ...
Soleno Therapeutics, Inc. has a one year low of $36.61 and a one year high of $60.92. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -14.79 and a beta of -1.70.
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?
Soleno Therapeutics Inc. (NASDAQ:SLNO) Soleno Therapeutics jumped by 37.61 percent on Thursday to end at $67.39 apiece as investors cheered news that it secured the approval of the Food and Drug ...
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare ...
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
Similar Companies
Loading the latest forecasts...